Cargando…
Familial Hypercholesterolemia (FH) in Iran: Findings from the Four-Year FH Registry
BACKGROUND: Familial hypercholesterolemia (FH) is a common autosomal dominant disease. Its diagnosis in Iran was uncommon. Iran registry of FH (IRFH) has been started from 2017 from Isfahan. In this study, we report the four-year FH registry. METHODS: The Iran FH registry is an ongoing study which i...
Autores principales: | Vaseghi, Golnaz, Taheri, Marzieh, Heshmat-Ghahdarijani, Kiyan, Rayati, Mohammad, Zarfeshani, Sonia, Pourmoghaddas, Ali, Khosravi, Alireza, Zarepour, Ehsan, Keshavarzrad, Parsa, Arabi, Sina, Azizi, Mohammadreza, Haghjooy Javanmard, Shaghayegh, Najafian, Jamshid, Sarrafzadegan, Nizal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213494/ https://www.ncbi.nlm.nih.gov/pubmed/34221513 http://dx.doi.org/10.1155/2021/9913969 |
Ejemplares similares
-
CASCADE screening and registry of familial hypercholesterolemia in Iran: Rationale and design
por: Vaseghi, Golnaz, et al.
Publicado: (2019) -
Hematological Inflammatory Markers in Patients with Clinically Confirmed Familial Hypercholesterolemia
por: Vaseghi, Golnaz, et al.
Publicado: (2022) -
Corrigendum to “Hematological Inflammatory Markers in Patients with Clinically Confirmed Familial Hypercholesterolemia”
por: Vaseghi, Golnaz, et al.
Publicado: (2023) -
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020) -
Apolipoprotein B gene mutation related to familial hypercholesterolemia in an Iranian population: With or without hypothyroidism
por: Vaseghi, Golnaz, et al.
Publicado: (2021)